Publications by authors named "Aifang Feng"

2 Publications

  • Page 1 of 1

The safety of clinically indicated replacement or routine replacement of peripheral intravenous catheters: A randomized controlled study.

J Vasc Access 2021 Mar 12:1129729821998528. Epub 2021 Mar 12.

Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.

Objective: The primary purpose of this study was to explore the safety of peripheral intravenous catheter (PIVC) replacement every 96 h compared to that of clinically indicated catheter removal.

Methods: A prospective, single-blind, randomized controlled trial was conducted. A random number table method was used. Six hundred patients treated with PIVC intravenous infusion in 10 nursing units of a hospital from September to October 2019 were selected. Sixty were collected from each nursing unit, including 30 in the clinically indicated replacement group and 30 in the routine replacement group. The incidence of phlebitis, catheter-related infection (CRI), occlusion, infiltration, and any form of infusion therapy failure were compared between the two groups. SPSS 23.0 software was used.

Results: The dwelling times of PIVC in the clinically indicated replacement group and routine replacement group were significantly different (hours) (83.62 ± 50.08, 69.75 ± 25.54,  = 3.021,  = 0.003). The incidence of any form of infusion therapy failure (RR = 4.448, 95% CI: 3.158-6.265,  < 0.001), phlebitis (RR = 2.416, 95% CI: 1.595-3.660,  < 0.001), occlusion (RR = 6.610, 95% CI: 3.062-14.268,  < 0.001), infiltration (RR = 2.607, 95% CI: 1.130-6.016,  = 0.020), accidental dislodgement (RR = 2.027, 95% CI: 1.868-2.200,  = 0.013), and pain at the insertion site (RR = 2.521, 95% CI: 1.742-3.649,  < 0.001) was higher in the clinically indicated replacement group than that in the routine replacement group. The overall survival curve of PIVC was drawn with Kaplan-Meier survival analysis. The median survival time of intravenous infusion was 59.58 h; the cumulative survival rates of 48 h, 72 h, and 96 h were 77.00%, 51.33%, and 20.33%, respectively.

Conclusion: Replacement of PIVC every 96 h is safer than clinically indicated.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1129729821998528DOI Listing
March 2021

ICAM-1 gene rs5498 polymorphism decreases the risk of coronary artery disease.

Medicine (Baltimore) 2018 Oct;97(40):e12523

Department of Emergency, the Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Background: Many studies investigated the association between intercellular adhesion molecule 1 (ICAM-1) gene rs5498 polymorphism and the risk of coronary artery disease (CAD). However, the results were inconsistent.

Methods: To clarify convincing association, we conducted a comprehensive meta-analysis by searching in PubMed, Embase, Web of sciences, Sciences citation index, Google scholar, Cochrane Library, and the CNKI databases. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results: A total of 29 case-control studies with 5,494 cases and 6,364 controls for rs5498 polymorphism were included. The studied populations of this meta-analysis included Caucasians and Asians. Meta-analysis showed that rs5498 polymorphism was associated with the decreased risk of CAD. Stratification analysis of ethnicity found that rs5498 polymorphism decreased the risk of CAD among Caucasians, but not among Asians. Stratification by type of CAD revealed that ICAM-1 gene rs5498 polymorphism was also correlated with the decreased risk of myocardial infarction (MI).

Conclusion: In conclusion, this meta-analysis indicates that ICAM-1 gene rs5498 polymorphism decreases the risk of CAD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012523DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200538PMC
October 2018
-->